- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07898774
A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients (PRESERVE)
A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis
To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The PRESERVE study is a Phase 3b, multicenter, single-arm, open-label clinical trial designed to explore the efficacy and safety of pegcetacoplan in preventing or delaying the recurrence of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) following kidney transplantation. Recurrence of these diseases after transplantation is common and can lead to graft dysfunction and loss. Pegcetacoplan is a complement C3/C3b inhibitor that has demonstrated activity in patients with native kidney disease and recurrent disease after transplantation. The study aims to assess whether initiating pegcetacoplan at the time of kidney transplantation, before recurrence occurs, may delay the recurrence and support long-term graft outcomes. Participants will receive pegcetacoplan in addition to standard post-transplant care and will be followed to evaluate disease recurrence, kidney function, graft outcomes, safety, and tolerability.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Study Physician
- Número de teléfono: +46 86972000
- Correo electrónico: medical.info@sobi.com
Ubicaciones de estudio
-
-
Lower Saxony
-
Hanover, Lower Saxony, Alemania, 30625
- Medizinische Hochschule Hannover
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Alemania, 50937
- Universitaetsklinikum Koeln
-
Essen, North Rhine-Westphalia, Alemania, 45147
- Universitaetsklinikum Essen
-
-
-
-
-
Riyadh, Arabia Saudita, 11211
- King Faisal Specialist Hospital & Research Center
-
-
-
-
Pernambuco
-
Recife, Pernambuco, Brasil, 52010-010
- Real Hospital Português
-
-
São Paulo
-
Botucatu, São Paulo, Brasil, 18618-970
- UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
-
São Paulo, São Paulo, Brasil, 05403-000
- Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSP
-
-
-
-
Alberta
-
Edmonton, Alberta, Canadá, T6G 2R7
- University of Alberta - Faculty of Medicine & Dentistry
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6Z 1Y6
- St. Paul's Hospital
-
-
Ontario
-
London, Ontario, Canadá, N6A 5A5
- London Health Sciences Centre (LHSC) - University Hospital
-
Toronto, Ontario, Canadá, M5G 2C4
- Toronto General Hospital
-
-
Quebec
-
Montreal, Quebec, Canadá, H4A 3J1
- McGill University Health Centre Research Institute
-
-
-
-
Barcelona
-
Barcelona, Barcelona, España, 8035
- Hospital Universitari Vall d'Hebron - VHIR
-
-
La Coruña
-
A Coruña, La Coruña, España, 15006
- Complejo Hospitalario Universitario A Coruña
-
-
Madrid
-
Madrid, Madrid, España, 28041
- Hospital Universitario 12 de Octubre
-
-
Málaga
-
Málaga, Málaga, España, 29010
- Hospital Regional Universitario de Malaga
-
-
Vizcaya
-
Barakaldo, Vizcaya, España, 48903
- Hospital de Cruces
-
-
-
-
-
Helsinki, Finlandia, 290
- Helsinki University Central Hospital
-
-
-
-
Bas Rhin
-
Strasbourg, Bas Rhin, Francia, 67091
- CHU Strasbourg - Nouvel Hôpital Civil
-
-
Haute Garonne
-
Toulouse, Haute Garonne, Francia, 31059
- Hopital Rangueil
-
-
Herault
-
Montpellier, Herault, Francia, 34000
- Hopital Lapeyronie pt
-
-
Nord
-
Lille, Nord, Francia, 59037
- Hopital Claude Huriez - CHU Lille
-
-
Paris
-
Paris, Paris, Francia, 75015
- Hôpital Necker - Enfants Malades
-
-
Rhone
-
Lyon, Rhone, Francia, 69437
- Hopital Edouard Herriot - CHU Lyon
-
-
-
-
Bari
-
Bari, Bari, Italia, 70124
- Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
-
-
Bergamo
-
Bergamo, Bergamo, Italia, 24127
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
-
Roma
-
Roma, Roma, Italia, 165
- Ospedale Pediatrico Bambino Gesù
-
Roma, Roma, Italia, 168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
-
-
-
Greater London
-
London, Greater London, Reino Unido, NW3 2QG
- Royal Free Hospital
-
London, Greater London, Reino Unido, W12 0HS
- Hammersmith Hospital
-
-
Greater Manchester
-
Manchester, Greater Manchester, Reino Unido, M13 9WL
- Manchester Royal Infirmary
-
-
Tyne & Wear
-
Newcastle upon Tyne, Tyne & Wear, Reino Unido, NE7 7DN
- Freeman Hospital
-
-
-
-
-
Lausanne, Suiza, 1011
- Centre Hospitalier Universitaire Vaudois (CHUV)
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female patients with a diagnosis of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) who are planning to undergo kidney transplantation because of the disease.
- Have a high risk of disease recurrence following kidney transplantation, based on either having a previous kidney allograft loss due to recurrence of C3G or primary IC-MPGN, or assessed as having a high risk by the investigator based on other clinical information.
- Is fully vaccinated and up to date with their vaccinations against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B, in accordance with local guidelines, at the time of initiating pegcetacoplan.
Exclusion Criteria:
- A known secondary cause for MPGN, including but not limited to monoclonal gammopathy of clinical significance, hepatitis B, hepatitis C, or autoimmune cryoglobulinemia.
- History of invasive meningococcal disease.
- History of malignancy, except for the following: cured basal or squamous cell skin cancer, curatively treated in situ disease, or currently malignancy-free and has been off-treatment for the malignancy for at least 5 years.
- Hypersensitivity to pegcetacoplan or any of its excipients.
- Known or suspected hereditary fructose intolerance.
- Any other medical condition which, in the opinion of the Investigator, makes the participant unsuitable for inclusion.
- Use of a complement inhibitor for the treatment of C3G or primary IC-MPGN within 1 month prior to the scheduled kidney transplantation surgery.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Pegcetacoplan
Pegcetacoplan, a complement C3/C3b inhibitor, administered according to the study protocol in kidney transplant recipients with high risk of recurring C3G or primary IC-MPGN |
Dose amount based on age and weight Subcutaneous infusion twice-a-week. Adult participants aged 18 years or older at enrolment: 1080 mg Adolescent participants aged 12 to 17 years at enrolment:
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Occurrence of Clinically Significant Recurrent Disease
Periodo de tiempo: Within 2 years after kidney transplantation
|
Histological evidence of recurrent disease based on the histopathological assessment of the kidney biopsy |
Within 2 years after kidney transplantation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to Onset of Clinically Significant Disease Recurrence
Periodo de tiempo: Up to 2 years after kidney transplantation
|
To explore the impact of pegcetacoplan on time to clinically significant recurrence of C3G or primary IC-MPGN after kidney transplantation |
Up to 2 years after kidney transplantation
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Study Physician, Swedish Orphan Biovitrum AB (publ)
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- Sobi.PEGCET-404
- 2026-526392-39-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Qualified researchers may request access to patient level data and related study documents.
All requests are evaluated by a cross functional panel of experts within Sobi. Patient level data will be anonymized and study documents, if applicable, will be redacted to protect the privacy of trial participants.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .